To evaluate the impact of eptinezumab on HRQoL across the spectrum of episodic migraine (EM) and chronic migraine (CM).

The Short-Form Health Survey (SF-36) is a well-established measure of HRQoL, with a score of ~50 representing the normative population mean. Eptinezumab, a humanized anti-CGRP monoclonal antibody, significantly reduced mean monthly migraine days (MMDs) in trials of EM (NCT02559895) and CM (NCT02974153).

Patients with ≤9 baseline MMDs had normative baseline mean Mental Component Summary (MCS) scores and Physical Component Summary (PCS) scores and experienced minimal changes at Wk4. Other subgroups had scores below normative at baseline. The changes from baseline at Wk4 in MCS in patients with 10-11 MMDs were +1.8 for eptinezumab 100mg, +2.1 for eptinezumab 300mg, and +0.7 for placebo; 12-14 MMDs were +2.9, +3.6, and -1.2 (respectively); 15-18 MMDs were +3.4, +4.2, and +0.5 (respectively); 19-22 MMDs were +3.7, +4.2, and +1.7 (respectively); and ≥23 MMDs were +3.3, +2.4, and +0.5 (respectively). Changes from baseline at Wk4 in PCS in patients with 10-11 MMDs were +3.0 (100mg), +3.9 (300mg), and +1.9 (placebo); 12-14 MMDs were +2.9, +3.6, and +2.0 (respectively); 15-18 MMDs were +3.7, +4.5, and +2.7 (respectively); 19-22 MMDs were +4.6, +5.1, and +3.3 (respectively); and ≥23 MMDs were +3.7, +7.1, and +1.5 (respectively). Clinically meaningful improvements were observed through Wk12.

In patients with diminished HRQoL, eptinezumab treatment demonstrated clinically meaningful improvements in SF-36 scores, beginning as early as 1 month, with greater improvements generally seen in patients with more MMDs at baseline.